Neuroscientists should not forget that brains have owners, a new genetic database makes its debut, and the intense interests of people with autism offer opportunities.

At least 83 percent of the United States’ largest patient advocacy groups take contributions from the drug industry, and not all of them are transparent about it.

The findings of a new analysis hint that a 2009 state law establishing the right to a medical interpreter is either not being fully enforced or is not being promoted widely enough.

Conventional wisdom holds that people with autism don’t get hooked on alcohol or other drugs, but new evidence suggests otherwise.

British scientists anxiously await their country’s departure from the European Union, President Trump’s views on vaccines may fuel a dangerous movement, and an ethicist helps keep gene-editing research in line.

The U.S. medical system depends on doctors from other countries, who often work in areas in desperate need of providers.

Robert Califf, the just-departed commissioner of the U.S. Food and Drug Administration, offers his take on the Trump administration’s plans to speed up drug approvals and dramatically reduce regulations at the agency.

Watch the complete replay of Deborah Fein’s webinar discussing a form of ‘optimal outcome’ in autism.

The Broad Institute can keep its CRISPR patents, Trump’s vaccine safety panel may be back on, and a drug discovered in fish eases seizures in children.

Clinical trials for autism drugs have been plagued with problems: bad design, the wrong measures, too broad a range of participants. All that is finally starting to change.